Aligos Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Aligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced the pricing of its underwritten public offering of 4,400,000 shares of common stock at a public offering price of $19.00 per share. In addition, Aligos has granted the underwriters a 30-day option to purchase up to an additional 660,000 shares of common stock at the same terms and conditions. All of the shares of common stock are being offered by Aligos. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Aligos, are expected to be approximately $83.6 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on July 6, 2021, subject to customary closing conditions.
Global Virus Network Analysis Suggests Measles, Polio and Tuberculosis Vaccines May Boost Immunity to Coronavirus
Innate Immunity Created by Live Attenuated Vaccines Like Measles and Polio May Provide Some Protection Against Future Pandemics - Idea Needs To Be Tested, Scientists Say
News provided by
Share this article
Share this article
BALTIMORE, May 18, 2021 /PRNewswire/ Members of the Global Virus Network (GVN), a coalition comprised of human and animal virologists from 63 Centers of Excellence and 11 Affiliates in 35 countries, and colleagues today published a perspective proposing that live attenuated vaccines (LAVs), such as those for tuberculosis, measles, and polio, may induce protective innate immunity that mitigate other infectious diseases, triggering the human body s natural emergency response to infections including COVID-19 as well as future pandemic threats.
Hummingbird Bioscience buzzes with $150M series C led by Novo Holdings fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.